Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness

Mujoomdar M, Clark M, Nkansah E
Record ID 32011001579
English
Authors' objectives:

Coronary artery disease (CAD) is a leading cause of morbidity and mortality in the Western world. Early detection, followed by treatment, may limit disease progression. Cardiac imaging using positron emission tomography (PET) can be used to evaluate CAD and to help identify patients who can undergo revascularization. Radionuclides are used in PET to assess the viability of the myocardium and left ventricular function. This report reviews the literature on the clinical effectiveness of PET in the diagnosis and management of CAD. The quality of guidelines on the use of PET in the management of CAD is also assessed.

Authors' recommendations: Overall, the evidence suggests that PET may be a useful tool in the diagnosis of CAD, particularly for patients with an intermediate likelihood of CAD, those who are obese, or those who are unable to exercise. The role of PET in the identification of patients with CAD who may benefit from revascularization is unclear. The lack of evidence from studies with high internal validity and the quality of the evidence that was used by the guideline development groups may be a consideration when deciding to use PET in the diagnosis or management of patients with CAD.
Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Cardiovascular Diseases
  • Positron-Emission Tomography
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.